Omega Therapeutics IPO Presentation Deck

Disclaimer and Forward-Looking Statements The material in this presentation and the accompanying oral presentation (this "Presentation") regarding Omega Therapeutics, Inc. ("we" or the "Company") is for informational purposes only. This Presentation shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. All statements other than statements of historical facts contained in this Presentation, including statements regarding our operations and financial position, business strategy, product candidate development, research and development activities and costs, timing and likelihood of success of our business plans, plans and objectives of management, future results and timing of clinical trials, plans for regulatory submissions, treatment potential of our product candidates, and the market potential of our product candidates, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. The words "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, but are not limited to, statements about the our ability to develop product candidates based on our novel technology, the potential benefits, activity, effectiveness and safety of our product candidates, the success and timing of our preclinical studies, plans for clinical trials, including the timing of regulatory submissions, the size and growth of the potential markets for our product candidates, the sufficiency of our cash resources, and need for additional financing, regulatory developments in the United States and other countries, the rate and degree of market acceptance of any product candidates we may develop, the implementation of our business model and strategic plans for our business and product candidates, our ability to obtain and maintain intellectual property protection for our product candidates, the hiring and retention of key scientific or management personnel and the anticipated trends and challenges in our business and the market in which we operate. These forward-looking statements are only predictions and we may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, so you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions, and expectations disclosed in the forward-looking statements we make. We have based these forward-looking statements largely on our current expectations and projections about future events and trends we believe may affect our business, financial condition, and operating results. The Company has filed a registration statement (including a prospectus) with the Securities and Exchange Commission (the "SEC") for the offering to which this presentation relates. The registration statement has not been declared effective. Before you invest, you should read the registration statement (including the prospectus), and in particular the "Risk Factors" contained therein, for more complete information about the Company and the proposed offering. You may obtain these documents for free by visiting EDGAR on the SEC website at www.sec.gov. Alternatively, you may request a copy of the prospectus by contacting Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, New York 10282, telephone: 1-866-471-2526, facsimile: 212-902-9316 or by emailing [email protected]; Jefferies LLC, Attn: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, New York 10022, by telephone at (877) 821-7388 or by email at [email protected]; or Piper Sandler & Co., 800 Nicollet Mall, J12S03, Minneapolis, Minnesota 55402, Attention: Prospectus Department, by telephone at (800) 747-3924 or by email at [email protected]. ©2021 Omega Therapeutics, Inc.

View entire presentation